secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUTRO BIOPHARMA, INC. (STRO)
CIK:        0001382101
Form:       8-K
Filed at:   2025-03-13T23:59:59+00:00
Accession:  0000950170-25-038879
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 2.05, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sutro restructures with 50% layoffs, deprioritizes luvelta; CEO Newell steps down, Jane Chung appointed
--------------------------------------------------------------------------------

- Jane Chung appointed CEO, replaces Bill Newell effective March 13, 2025; CFO and CMO also transitioning.
- Workforce reduced ~50%; luvelta (STRO-002) development halted; out-licensing sought.
- Cash, cash equivalents & marketable securities $316.9M as of Dec 31, 2024; cash runway into at least Q4 2026.
- Restructuring costs estimated $40-$45 million, largely in 2025; revenue $62M in FY2024 vs $153.7M in 2023.
- Three IND filings planned over next 3 years: STRO-004 (Tissue Factor ADC) expected 2H 2025, STRO-006 in 2026, dual-payload ADC in 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382101/000095017025038879/0000950170-25-038879-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382101/000095017025038879/stro-20250313.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-038879

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer